Fig. 6

Toxicity of nintedanib, paclitaxel, PD-L1 antibody and the combinations in the EMT-6 and EMT-6/CDDP models. a) EMT-6 primary tumor model, b) EMT-6/CDDP primary tumor model, and c) advanced metastasis EMT-6/CDDP model. a) Treatments were in general well tolerated. b and c) Mice showed signs of toxicity in response to nintedanib and paclitaxel (PTX) at the beginning of therapy with no significant associated loss of body weight, but later they recovered. Toxicity associated with PD-L1 therapy did not affect body weight. Body weight is considered as a surrogate for toxicity in mice. Data are presented as means ± SD. n = 6 (a), n = 9–12 (b), n = 8 (c)